Abstracts tagged "Pharmacoepidemiology"

Abstract Number: 1005 • ACR Convergence 2024
Pharmacosurvellience Study of FDA Adverse Event Reporting System (FAERS) Events of Tofacitinib and Upadacitinib
Nur Barlas, Sait Barlas, Stefan Milutinovic and Shristi Basnyat, Florida State University College of Medicine Internal Medicine Residency Program at Lee Health, Cape Coral
Background/Purpose: Janus Kinase (JAK) inhibitors are the agents of choice for the treatment of rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis when other DMARDs are…
Abstract Number: 2566 • ACR Convergence 2024
Detrimental Effects of Proton Pump Inhibitors on Bone Mineral Density Are Not Mediated by Changes in Serum Calcium or Parathyroid Hormone in Patients with Inflammatory Rheumatic Diseases: A Cross-sectional Study
andriko Palmowski¹, Zhivana Boydzhieva², Paula Hoff³, Sandra Hermann³, burkhard Muche³, David Simon⁴, Gerhard Krönke³, Edgar Wiebe⁵ and FRANK HARTMUT DR. BUTTGEREIT⁵, ¹Charité - Universittsmedizin Berlin, Berlin, Germany, ²Charité Universittsmedizin, Berlin, Germany, ³Rheumatology, Charité, Berlin, Germany, ⁴Department of Rheumatology and Clinical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany/ Department of Internal Medicine 3, University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany/Deutsches Zentrum für Immuntherapie (DZI), University of Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Berlin, Germany, ⁵Charité University Medicine Berlin, Berlin, Germany
Background/Purpose: In a previous study, we found daily proton pump inhibitor (PPI) intake to be associated with decreased bone mineral density in patients with inflammatory…
Abstract Number: 1049 • ACR Convergence 2024
Very Low Uptake of Biosimilar Adalimumab in the First 9 Months of Availability in Rheumatology
Eric Roberts¹, Gabriela Schmajuk² and Jinoos Yazdany³, ¹University of California, San Francisco, SF, CA, ²UCSF / SFVA, San Francisco, CA, ³UCSF, San Francisco, CA
Background/Purpose: In 2021, over 300,000 patients in the United States used adalimumab, making it one of the highest-grossing drugs globally. In 2023, patent exclusivity for…
Abstract Number: 2609 • ACR Convergence 2024
Drivers of Infliximab Biosimilar Uptake: A Comparative Analysis of New Biosimilar Initiations versus Switching in a National Rheumatology Registry
Eric Roberts¹, Nick Bansback², Chien-Wen Tseng³, Steve Shiboski⁴, Jing Li⁵, Gabriela Schmajuk⁶ and Jinoos Yazdany⁷, ¹University of California, San Francisco, SF, CA, ²University of British Columbia, Vancouver, BC, Canada, ³University of Hawai'i John A. Burns School of Medicine, Honolulu, ⁴University of California, San Francisco, San Francisco, ⁵University of California, San Francisco, San Francisco, CA, ⁶UCSF / SFVA, San Francisco, CA, ⁷UCSF, San Francisco, CA
Background/Purpose: Biosimilars hold promise for reducing pharmaceutical expenditures, however uptake has lagged. We analyzed the variability in new biosimilar starts and switching from bio-originator infliximab…
Abstract Number: 1073 • ACR Convergence 2024
Dashboard Utilization and Order Menu Revision Improve HLA-B*5801 Testing Prior to Allopurinol Initiation in High-Risk Patients in a Veteran-based Primary Care Setting
Catherine Vo, Chialin Nguyen, Scott Hagan, Sheida Aalami and Elizabeth Wahl, VA Puget Sound Healthcare System, Seattle, WA
Background/Purpose: The 2020 ACR Guideline for the Management of Gout conditionally recommends testing for the HLA-B*5801 risk allele prior to starting allopurinol for patients of…
Abstract Number: 1189 • ACR Convergence 2024
Certain Dosages of Fasinumab Provides Superior Benefits over Placebo in Mitigating Osteoarthritis Symptoms Albeit at Increased Health Detriments: A Systematic Review and Meta-Analysis
Muhammad Sohaib Khan¹, Wania Moeen², Umm E Salma Shabbar Banatwala², Muhammad Usman², Umar Mahmood², Syed Ashad Ahmed Fatmi², Syed Muhammad Muneeb Akhtar², Hania Shahzad³, Muhammad Talal Ibrahim⁴, Nisar Ahmed⁵, Badaruddin Sahito² and Muhammad Sohaib Asghar⁶, ¹Dow University of Health Sciences, Karachi, Pakistan, ²Dow University of Health Sciences, Karachi, Sindh, Pakistan, ³UC Davis Health, Sacramento, CA, ⁴The Ohio State University Wexner Medical Center, Columbus, OH, ⁵Rapido’s Clinica Familiar, Chicago, ⁶AdventHealth, Sebring, FL
Background/Purpose: Fasinumab, a newly developed anti-nerve growth factor monoclonal antibody, is currently under investigation for its potential to alleviate symptoms in osteoarthritis patients. This meta-analysis…
Abstract Number: 1214 • ACR Convergence 2024
All-Cause Mortality in Patients with Chronic Musculoskeletal Pain Using Pregabalin or Duloxetine: A Retrospective Cohort Study in US Veterans
Sachalee Campbell¹, Laura L. Daniel², Alyson L. Dickson³, Otis Wilson³, C. Michael Stein³, Puran Nepal⁴, Adriana M. Hung⁵ and Cecilia P. Chung², ¹University of Miami/ Jackson Health System, Miami, FL, ²University of Miami, Miami, FL, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Vanderbilt University Medical Center, Vanderbilt, TN, ⁵Veterans Administration Tennessee Valley Healthcare System, Nashville, TN
Background/Purpose: Musculoskeletal pain affects more than 10% of the general population. Recent trends in managing chronic musculoskeletal pain have favored non-opioid analgesics, for example, pregabalin,…
Abstract Number: 1215 • ACR Convergence 2024
Mortality in US Veterans with Musculoskeletal Conditions Using Cyclobenzaprine or Baclofen
Maria Intriago¹, Puran Nepal², Laura L. Daniel¹, Alyson L. Dickson³, Otis Wilson³, C. Michael Stein³, Adriana M. Hung⁴ and Cecilia P. Chung¹, ¹University of Miami, Miami, FL, ²Vanderbilt University Medical Center, Vanderbilt, TN, ³Vanderbilt University Medical Center, Nashville, TN, ⁴Veterans Administration Tennessee Valley Healthcare System, Nashville, TN
Background/Purpose: Cyclobenzaprine is a commonly-used centrally-acting muscle relaxant; it has been approved for short-term treatment of muscle spasms associated with acute musculoskeletal pain despite limited…
Abstract Number: 0152 • ACR Convergence 2024
Hydroxychloroquine and Chloroquine Retinopathy in Hispanic Patients with Rheumatic Diseases
Janett Riega Torres¹, Karina Palomo-Arnaud², Gabriel Figueroa-Parra¹, Fernando Morales Wong¹, Jesús Hernán González Cortés¹, Jesus Mohamed Hamsho¹, Jorge Esquivel-Valerio¹, Dionicio Galarza-Delgado³ and Karim Mohamed Noriega¹, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, ³UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Antimalarial drugs like hydroxychloroquine (HCQ) and chloroquine (CQ) are among the most frequently prescribed medications in Rheumatology. Retinal toxicity is an unwanted side effect…
Abstract Number: 1270 • ACR Convergence 2024
Association of Disease-Modifying Anti-Rheumatic Drug Selection with Hospitalized Infection in Youth with Childhood-Onset Systemic Lupus Erythematosus
Jordan Roberts¹, Anna Faino², Marshall Brown³, Gabrielle Alonzi⁴, Mersine Bryan⁵, Cordelia Burn⁶, Joyce Chang⁴, Jonathan Cogen⁷, Nidhi Naik⁸, Kareena Patel⁹, Emily Zhang⁴, Mary Beth Son¹⁰ and Esi Morgan¹, ¹Seattle Children's Hospital, Seattle, WA, ²Seattle Children's Research Institute, Core for Biostatistics, Epidemiology and Analytics in Research, Seattle, ³Core for Biostatistics, Epidemiology and Analytics in Research, Seattle Children's Research Institute, Seattle, WA, ⁴Boston Children's Hospital, Boston, MA, ⁵Division of Hospital Medicine, Seattle Children's Hospital, Seattle, WA, ⁶Seattle Children's Hospital, Boston Children's Hospital, Seattle, ⁷Seattle Children’s Hospital, Seattle, WA, ⁸Seattle children's hospital, Bothell, WA, ⁹Seattle Children's Hospital, Seattle, ¹⁰Boston Children's Hospital, Brookline, MA
Background/Purpose: Youth with childhood-onset systemic lupus erythematosus (cSLE) have increased risk of serious infection. It is unknown how much of this risk is due to…
Abstract Number: 0159 • ACR Convergence 2024
Prevalence and Potential Factors Associated with Polypharmacy in Individuals with Systemic Lupus Erythematosus
Jianing Yang¹, Jinoos Yazdany², S. Sam Lim³, Brad Pearce³ and Laura Plantinga⁴, ¹Highland Hospital, AHS, San Leandro, CA, ²UCSF, San Francisco, CA, ³Emory University, Atlanta, GA, ⁴University of California, San Francisco, San Francisco, CA
Background/Purpose: Polypharmacy is associated with an increased risk of adverse drug effects and medication nonadherence. However, the prevalence of polypharmacy and the medications and factors…
Abstract Number: 1439 • ACR Convergence 2024
Risk of Hip and Spine Fractures in Axial Spondyloarthritis Is Associated with Treatment Class
Devin Driscoll¹, Navya George², S. Reza Jafarzadeh³, Christine Peloquin³, Jean Liew³ and Maureen Dubreuil⁴, ¹Boston Medical Center, Boston, MA, ²Boston University Medical Center Internal Medicine Residency Program, Boston, MA, ³Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁴Section of Rheumatology, Boston University School of Medicine, Boston, MA
Background/Purpose: Individuals with axial spondyloarthritis (axSpA) have a risk of fracture that is nearly double that of the general population, possibly related to chronic inflammation.…
Abstract Number: 0268 • ACR Convergence 2024
Weight Loss Induced by Anti-obesity Medications and Gout Among Overweight and Obesity Individuals: A Population-based Cohort Study
Jie Wei¹, Yilun Wang², Nicola Dalbeth³, Junqing Xie⁴, Jing Wu⁵, Chao Zeng⁶, Guanghua Lei⁷ and Yuqing Zhang⁸, ¹Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic), ²Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China (People's Republic), ³University of Auckland, Auckland, New Zealand, ⁴Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ⁵Hunan Key Laboratory of Joint Degeneration and Injury, Changsha, China (People's Republic), ⁶Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University; Department of Epidemiology and Health Statistics, Xiangya School of Public Health, Central South University, Changsha, China (People's Republic), ⁷Department of Orthopaedics, Xiangya Hospital, Central South University; Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University; Hunan Key Laboratory of Joint Degeneration and Injury, Xiangya Hospital, Central South University; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China (People's Republic), ⁸Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Harvard Medical School; The Mongan Institute, Massachusetts General Hospital, Harvard Medical School, Boston, MA
Background/Purpose: Weight loss is conditionally recommended for gout management; however, the magnitude of the effect of weight loss on incident gout and recurrent gout flares…
Abstract Number: 1713 • ACR Convergence 2024
Comparisons of Non-TNFi Biologic and Targeted Synthetic DMARDs in Rheumatoid Arthritis-Associated Interstitial Lung Disease: A Propensity Score-Matched Study Using National Veterans Affairs Data
Halie Frideres¹, Christopher Wichman², Jianghu Dong³, Punyasha Roul⁴, Yangyuna Yang², Joshua Baker⁵, Michael George⁶, Tate Johnson², Jorge Rojas⁷, Sauer brian⁸, grant Cannon⁹, Scott Matson¹⁰, Jeffrey Curtis¹¹, Ted Mikuls² and Bryant England², ¹UNMC Department of Rheumatology, Omaha, NE, ²University of Nebraska Medical Center, Omaha, NE, ³University of Nebraska Medical Center, Omaha, ⁴UNMC, Omaha, NE, ⁵Department of Medicine, Perelman School of Medicine University of Pennsylvania, Philadelphia, PA, ⁶University of Pennsylvania, Philadelphia, PA, ⁷Seattle VA, Mexico, Mexico, ⁸Salt Lake City VA/University of Utah, Salt Lake City, UT, ⁹University of Utah and Salt Lake City VA, Salt Lake City, UT, ¹⁰University of Kansas, Kansas City, MO, ¹¹University of Alabama at Birmingham, Hoover, AL
Background/Purpose: Recent RA-interstitial lung disease (RA-ILD) treatment guidelines noted a paucity of evidence on the comparative effectiveness and safety of DMARDs in RA-ILD. Previously, TNFi…
Abstract Number: 0509 • ACR Convergence 2024
Trends in Initiation of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among Commercially-Insured US Adults, 2001-2021
Lydia Lee¹, Jeffrey Sparks², Priyanka Yalamanchili¹, Daniel B. Horton³, Zeba Khan⁴, Joseph Barone⁴ and Chintan Dave⁵, ¹Rutgers University, New Brunswick, NJ, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ³Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Department of Biostatistics and Epidemiology, Rutgers School of Public Health; Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Rutgers University, New Brunswick, ⁵Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, New Brunswick, NJ
Background/Purpose: Despite the increasing availability of newer RA therapies, there is a paucity of data comprehensively evaluating long-term trends for individual DMARDs in the US.…

1
2
3
…
7
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].